Marianne Sarrazin is a partner in the firm’s Life Sciences group. With a focus on the biotech and medtech industries, she regularly advises such companies on going public — via traditional IPO or alternative path to public (reverse merger or deSPAC). Marianne also frequently serves as outside general counsel to her public company clients, closely advising management teams and boards of directors on a wide variety of matters, including ongoing SEC reporting and US securities law requirements, as well as Nasdaq compliance and other corporate governance matters, including diversity initiatives. She also routinely represents clients — both US and foreign private issuers — in public and private capital markets transactions including follow-on offerings, at-the-market offerings and PIPEs.